Eli Lilly reported a 39% revenue increase to $24.4 billion in Q3 2026, led by strong sales of Mounjaro and Zepbound. Earnings per share rose 16% to $7.22 on a reported basis, with the company raising its full-year revenue guidance to $91-$92 billion. Key regulatory approvals and positive clinical trial results support future growth, alongside recent acquisitions to expand its pipeline in mental health and autoimmune diseases. Lilly continues investing in manufacturing and technology to sustain long-term growth.
Following Eli Lilly's strong Q3 2026 results and raised guidance, its stock price on Pluang rose 3.97% to USD 1,340.00 as of Oct 29, 2026 18:02 WIB. The company holds a market cap of $1.15 trillion on the platform, with investors typically holding shares for 94 days. Buy orders dominate at 71%, reflecting continued interest in Lilly's growth prospects.
Eli Lilly will report its third-quarter earnings and revenue, expected to be boosted by strong sales of its obesity drug Zepbound and diabetes treatment Mounjaro. Investors are also watching the performance of Foundayo, an obesity pill launched in Ap...
A recent survey shows 16% of large employers are thinking about dropping coverage for GLP-1 weight-loss drugs due to high costs, up from 9% last year. This shift could reduce employer-paid prescriptions but may increase cash purchases by patients, af...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
Eli Lilly announced that Patrik Jonsson, executive vice president and president of Lilly International, will retire at the end of 2026 after a 36-year career. Starting January 1, 2027, Ilya Yuffa will take on an expanded role as executive vice presid...
